British drugmaker AstraZeneca said Monday that its coronavirus vaccine has generated a similar immune response in older and younger adults alike.
AstraZeneca, working with the University of Oxford to develop a vaccine, said adverse responses to its vaccine candidate among the elderly were also found to be lower, CNBC reported.
“It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher,” an AstraZeneca spokesman told CNBC via email. “The results further build the body of evidence for the safety and immunogenicity of” the vaccine.
As of Monday, more than 43.2 million coronavirus cases and 1.15 million related deaths have been reported worldwide, according to a Johns Hopkins University tracker.
